Possible new therapeutic strategy to regulate atopic dermatitis through upregulating filaggrin expression

Area of Science:

• Dermatology
• Genetics
• Pharmacology

Background:

• Nonsense mutations in filaggrin (FLG) are a key genetic cause of atopic dermatitis (AD).
• Identifying therapeutic targets that modulate FLG expression is crucial for AD treatment.

Purpose of the Study:

• To discover drug candidates that upregulate FLG expression.
• To investigate if enhanced FLG expression can prevent AD development.

Main Methods:

• Screened a bioactive library using an FLG reporter assay in HaCaT cells.
• Evaluated compound effects on keratinocytes using a human skin equivalent model.
• Assessed compound efficacy in an NC/Nga mouse model of AD-like skin inflammation.

Main Results:

• JTC801 significantly increased FLG mRNA and protein expression in human keratinocytes.
• JTC801 promoted FLG expression without affecting other keratinocyte differentiation markers in a skin model.
• Oral JTC801 administration elevated FLG protein levels and reduced AD-like inflammation in mice.

Conclusions:

• JTC801 is the first compound shown to increase FLG expression and reduce AD-like skin inflammation.
• Modulating FLG expression represents a potential novel therapeutic approach for atopic dermatitis.
• This study provides a foundation for developing FLG-targeting therapies for AD.